2015
Chapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment
Turan V, Oktay K. Chapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment. 2015, 47-61. DOI: 10.1016/b978-0-12-801591-9.00004-7.Peer-Reviewed Original ResearchCancer treatmentComplications of chemotherapySystemic lupus erythematosusPremature ovarian insufficiencyQuality of lifeOvarian damageLupus erythematosusOvarian toxicityAutoimmune diseasesOvarian functionBRCA mutationsReproductive ageRelative riskChemotherapy agentsClinical dataOvarian insufficiencySurvival rateChemotherapeutic agentsOvarian cellsChemotherapyHuman dataTreatmentCurrent understandingErythematosusComplications
2009
Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility?
Oktay K, Kim J, Barad D, Gleicher N, Babayev S. Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility? Journal Of Clinical Oncology 2009, 27: 11039-11039. DOI: 10.1200/jco.2009.27.15_suppl.11039.Peer-Reviewed Original ResearchRelative riskOvarian reserveBRCA mutationsBreast cancerFertility preservationHereditary breast-ovarian cancer syndromeOocyte reserveBRCA1 mutationsBreast-ovarian cancer syndromeOvarian stimulation protocolsDiminished ovarian reservePreservation of fertilityPossible higher riskOvarian cancer syndromeNumber of oocytesBreast/ovarian cancerPoor response ratesInfertility historyPoor respondersBC patientsMean ageNon-invasive methodOvarian failureOvarian cancerBRCA2 mutations